Updates

** Shares of drug developer Forte Biosciences FBRX.O rise 36.9% to $28.18

** Co says its experimental drug, FB102, showed a statistically significant benefit in an early-stage study for vitiligo, an autoimmune condition that causes patches of skin to lose color

** Says patients treated with FB102 showed a 29.6% average improvement in facial vitiligo at week 24; benefit was seen by day 64 and continued after treatment ended

** Adds in patients with greater disease involvement, FB102 showed a 43.2% average improvement at Week 24

** Co says FB102 was generally well tolerated, with only mild to moderate side effects

** Data add to earlier positive findings in celiac disease, an autoimmune disorder triggered by gluten; results from an ongoing mid-stage celiac disease study are expected soon - FBRX

** Including session's move, FBRX up 8.3% YTD